vandetanib

Overview

Vandetanib is an oral multi-kinase inhibitor targeting RET, VEGFR2, and EGFR. It is approved for unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).

Evidence in the corpus

• Activating RET mutations in metastatic medullary thyroid carcinoma patients identified by WGTA (POG program) guided vandetanib selection; patient PN7 subsequently received selpercatinib with 1423 days of stable disease PMID:24326773

Resistance mechanisms

Cancer types (linked)

• MTNN

Sources

This page was processed by crosslinker on 2026-05-09.